• Genetic Testing Transforms Medication Prescribing for Better Patient Outcomes

    Clinical Research News | The UK National Health Service’s PROGRESS trial has achieved remarkable clinical success, with one in four patients having their prescriptions adjusted based on genetic test results, leading to safer and more effective treatments. The PROGRESS trial’s interim results reveal that 95% of the 500 patients tested carried genetic variants that directly influence how they metabolize common medications.

    Jun 18, 2025

  • AI Agent Speeds Up Trials with Instant, Personalized Participant Interactions

    Clinical Research News | An artificial intelligence (AI) agent known as Grace is bringing clinical trials some much-needed speed and cost reduction and delivering more personalized, on-demand digital experiences for participants. Developed by fast-growing Grove AI, Grace has over the past year powered more than 50 phase 2 and 3 trials involving over 500,000 interactions with would-be and enrolled trial participants.

    Jun 17, 2025

  • IQVIA, NVIDIA Build AI Agents for Clinical Research

    Clinical Research News | Today, IQVIA announced multiple AI orchestrator agents in collaboration with NVIDIA. These specialized agentic systems—covering trial start-up, target identification, clinical data review, and more—are designed to manage and accelerate drug development workflows for IQVIA customers.

    Jun 11, 2025

  • Clinical Research Reveals Third Castleman Disease Subtype After 45 Years

    Clinical Research News | Researchers have made a landmark discovery in rare disease clinical research by identifying a new subtype of Castleman disease, marking the first major advancement in disease classification since the 1970s. The breakthrough demonstrates how patient-driven research registries can overcome traditional barriers in rare disease studies to generate clinically meaningful insights.

    Jun 10, 2025

  • Bridging the Gap Between GI Research and Routine Practice

    Clinical Research News | Gastroenterology is seeing meaningful progress in clinical research. New therapies for inflammatory bowel disease, colorectal cancer, and metabolic dysfunction-associated steatohepatitis (MASH) are being developed with increasing speed and precision. Yet for many community-based practices, participating in that research remains a significant challenge.

    Jun 6, 2025